Innovating Diabetes Care: DexCom's Vision for a Healthier Future
Second Quarter 2026 Financial Highlights: A Snapshot of Success
For the second quarter of 2026, DexCom achieved a worldwide revenue of $1.31 billion, marking a 13% increase on a reported basis and 12% organically compared to the second quarter of 2025. U.S. revenue reached $933 million, up 11% year-over-year, propelled by a surge in new patients and market share gains. International revenue climbed to $375 million, growing 19% on a reported basis and 16% organically, with significant contributions from France and Canada. The non-GAAP gross profit margin improved by 400 basis points to 64.1%, reflecting manufacturing efficiencies and optimized shipping. Non-GAAP operating income was $328.3 million, or 25.1% of revenue, a substantial increase from the prior year. Non-GAAP EPS rose by 46% to $0.70. Free cash flow for the first half of 2026 more than doubled to $600 million, contributing to a strong cash and marketable securities position of approximately $1.9 billion. Additionally, the company repurchased $600 million in shares during the quarter as part of a $1 billion authorization for fiscal year 2026. DexCom also raised its fiscal year 2026 revenue guidance to $5.18 billion to $5.25 billion, operating margin to 23.5%-24%, and gross profit margin to approximately 64%.
Key Strategic Initiatives and Product Advancements
DexCom's strategic focus centers on expanding continuous glucose monitoring (CGM) access for all individuals, enhancing customer experience, and increasing international market share. A major milestone is the CONNECT trial, which demonstrated a 1.6% A1C improvement for non-insulin-using Type 2 diabetes patients using DexCom CGM, surpassing previous landmark studies. This robust evidence supports broader reimbursement, with commercial coverage now extended to over 7 million Type 2 non-insulin users across major pharmacy benefit managers. DexCom is also the first participant in the FDA's Tempo digital device pilot, aiming to leverage CGM for prediabetes screening and metabolic health improvement. Product innovations include the redesigned Stello app, offering consumer-friendly features and AI-driven insights, and the DexCom Smart Basal, which accelerates optimal basal insulin titration for patients. The G7 15-day system rollout is progressing well, with Health Canada granting the first international approval, and the advanced G8 system, featuring a multi-analyte platform and smaller design, is targeted for late 2027 or early 2028.
Navigating Challenges and Sustaining Momentum
Despite significant advancements, DexCom acknowledges potential headwinds. Foreign exchange rate fluctuations are projected to impact international revenue by approximately $15 million in the second half of 2026. The launch of the Ireland manufacturing facility will involve initial hiring and training costs, alongside future depreciation, which will temporarily affect operating expenses before contributing to long-term efficiencies. However, the company's strong operational discipline has enabled it to achieve operating leverage ahead of schedule, reflecting effective cost management and funding for growth opportunities. The acquisition of Nutrisense, focused on integrating technology-driven nutrition insights, is expected to enhance the digital platform, though its non-CGM revenue contribution remains minimal in the near term. DexCom remains committed to its growth vision, backed by a compelling cash flow and margin profile, and a dedicated workforce driving its mission forward.
Future Outlook: Expanding Global Reach and Impact
DexCom's vision extends beyond current achievements, aiming to help millions more people worldwide. The company is actively engaged in advocacy, access expansion, and product development to broaden its market opportunity. The anticipated CMS decision on coverage for the non-insulin Type 2 population, expected by year-end 2026 with an estimated effective date in mid-2027, could revolutionize diabetes care in the U.S. DexCom's commitment to continuous innovation, exemplified by the G8 system and the Stello app, ensures that its technology remains at the forefront of metabolic health management. The global rollout of the 15-day sensor across international markets, following its approval in Canada, signifies a steady and positive progression towards wider accessibility. With sustained focus on customer experience, operational excellence, and strategic partnerships, DexCom is poised for a future of continued growth and profound impact on global health.